National Institutes of Health, a Component of the US Dept. of Health & Human Services

Hospital Clinic De Barcelona

British Columbia Cancer Agency Branch

UniversitÄt De Barcelona

Oslo University Hospital Hf

Julius-maximilians-university of Wurzburg

University of Arizona

University of Nebraska

Oregon Health & Science University

The Cleveland Clinic Foundation

University of Rochester

University of London

Mayo Foundation for Medical Education and Research

City of Hope

Julius-maximilians-universitaet Wuerzburg

Erlend B Smeland

Louis M Staudt

Elaine S Jaffe

Joseph M Connors

Jan Delabie

German Ott

Lisa M Rimsza

Wing C Chan

Dennis Weisenburger

Randy D Gascoyne

Kai Fu

George W Wright

Rita M Braziel

David William Scott

James Robert Cook

Elias Campo Guerri

Wyndham H Wilson

Sandeep S Dave

Andreas Rosenwald

Harald Holte

Hans-Konrad Muller-Hermelink

Timothy C Greiner

Armando Lopez-Guillermo

Richard I Fisher

Pedro Jares

George Wright

Chih-Jian Lih

Randy Gascoyne

Raymond Tubbs

Georg Lenz

Timothy Greiner

Anja Mottok

Andrew T Lister

Hans-Konrad Müller-Hermelink

Paul Michael Williams

Stein Kvaloy

Thomas M Grogan

Bruce Tan

Christian Steidl

Stein Kvaløy

Lisa Rimsza

John I Powell

James Armitage

Thomas Miller

T Andrew Lister

Julie Vose

Silvia M Bea

Andreas Zettl

Victor Moreno

Itziar Salaverria

Emilio Montserrat

Pau Abrisqueta

Rita Braziel

Diego Villa

Graham Slack

Joo Song

C Chan Wing

HWilson Wyndham

Dennis D Weisenburger

James R Cook

The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.

Evaluation of mantle cell lymphoma and methods related thereto

In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.

Method for determining lymphoma type and providing treatment

The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

Method for subtyping lymphoma types by means of expression profiling

The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Survival predictor for diffuse large B cell lymphoma

Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

Methods for identifying, diagnosing, and predicting survival of lymphomas

Growing community of inventors

Oslo, Norway

Erlend B Smeland